journal article·2017-02-17Open access

Development and evaluation of targeting ligand-anchored CNTs as prospective targeted drug delivery system

Sumandeep Kaur, Neelesh Kumar Mehra, Keerti Jain, Narendra Kumar Jain

Abstract

Our main investigation in the present research was to developt and evaluate targeting ligand-anchored multiwalled carbon nanotubes (MWCNTs) as prospective targeted drug delivery system, with a special focus on the MWCNTs surface functionalization (FA-PEG bis-amine functionalized, carboxylated MWCNTs). In vitro release of 5-fluorouracil (5-FU) was studied at pH 7.4 phosphate buffer and 5.5 acetate buffer, which displayed initial faster followed by sustained release up to 900 min. Further, 5-FU/FA-PEG bis amine-MWCNTs was found to be long circulating, prolonged half-life and increased drug accumulation in target tissue.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Carbon Nanotubes in Composites · Graphene and Nanomaterials Applications · Fullerene Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy, Moga, Punjab, India;

Department of Pharmaceutical Sciences, Pharmaceutics Research laboratory, R. H. S. Gour University, Sagar, Madhya Pradesh, India

References (38)

Show source-provided references
1. 10.1016/j.biomaterials.2009.03.01610.1016/j.biomaterials.2009.03.016 ↗
2. 10.1016/j.ejpb.2012.04.00210.1016/j.ejpb.2012.04.002 ↗
3. 10.1038/363605a010.1038/363605a0 ↗
4. 10.1016/S0378-5173(03)00132-710.1016/S0378-5173(03)00132-7 ↗
5. 10.1016/j.biomaterials.2008.05.01610.1016/j.biomaterials.2008.05.016 ↗
6. 10.1021/jp011489110.1021/jp0114891 ↗
7. 10.1021/mp300701e10.1021/mp300701e ↗
8. 10.1016/j.carbon.2008.02.01210.1016/j.carbon.2008.02.012 ↗
9. De la Cruz EF · Int J Electrochem Sci · 2012 · 7 · 357710.1016/S1452-3981(23)13979-4 ↗
10. Hirlekar R · Asian J Pharm Clinl Res · 2009 · 2 · 17
11. 10.1016/j.addr.2011.04.00110.1016/j.addr.2011.04.001 ↗
12. 10.1007/s00339010092910.1007/s003390100929 ↗
13. 10.1038/363603a010.1038/363603a0 ↗
14. 10.1038/354056a010.1038/354056a0 ↗
15. 10.1016/j.nano.2009.03.00110.1016/j.nano.2009.03.001 ↗
16. 10.3109/1061186X.2015.107784610.3109/1061186X.2015.1077846 ↗
17. 10.1016/j.colsurfa.2006.10.02210.1016/j.colsurfa.2006.10.022 ↗
18. 10.3109/1061186X.2012.72921310.3109/1061186X.2012.729213 ↗
19. 10.1590/S1984-8250201300010001310.1590/S1984-82502013000100013 ↗
20. 10.1615/CritRevTherDrugCarrierSyst.v25.i2.2010.1615/CritRevTherDrugCarrierSyst.v25.i2.20 ↗
21. 10.1016/j.drudis.2015.01.00610.1016/j.drudis.2015.01.006 ↗
22. 10.3109/1061186X.2013.81302810.3109/1061186X.2013.813028 ↗
23. 10.1016/j.colsurfb.2015.04.05610.1016/j.colsurfb.2015.04.056 ↗
24. 10.1021/mp500720a10.1021/mp500720a ↗
25. 10.3109/1061186X.2015.105557110.3109/1061186X.2015.1055571 ↗
26. 10.1016/j.drudis.2015.11.01110.1016/j.drudis.2015.11.011 ↗
27. 10.1016/j.biomaterials.2014.02.02210.1016/j.biomaterials.2014.02.022 ↗
28. Mittal V · Int J Pharm Bio Sci · 2010 · 1 · 1
29. 10.3109/1061186X.2012.69716810.3109/1061186X.2012.697168 ↗
30. 10.1016/j.biomaterials.2012.01.02510.1016/j.biomaterials.2012.01.025 ↗
31. Sharma P · Curr Drug Deliv · 2015
32. 10.1021/bm900162410.1021/bm9001624 ↗
33. 10.1021/bc800125u10.1021/bc800125u ↗
34. 10.1039/C5TB02088C10.1039/C5TB02088C ↗
35. 10.3109/21691401.2015.101967010.3109/21691401.2015.1019670 ↗
36. 10.1016/j.biomaterials.2013.09.03610.1016/j.biomaterials.2013.09.036 ↗
37. 10.2174/1874088X0110501024210.2174/1874088X01105010242 ↗
38. 10.1080/1061186090273792010.1080/10611860902737920 ↗